Skip to Main Content

The first clinical trial using genome editing to treat real patients is nearing an early but crucially important data reveal.

Until now, the only data available involving the removal or repair of disease-causing DNA have come from experiments in test tubes and animals. But late last year, the biotech company Sangamo Therapeutics started a clinical trial using a one-time, genome-editing fix to treat people born with a rare, inherited disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.